Methylation status of<i>IGFBP-3</i>as a useful clinical tool for deciding on a concomitant radiotherapy

Pernía, Olga; Belda-Iniesta, Cristóbal; Pulido, Verónica; Cortes-Sempere, María; Rodríguez, C. O.; Vera, Olga; Soto, Javier; Jiménez, J. Torres; Taus, Álvaro; Rojo, Federico; Arriola, Edurne; Rovira, Ana; Albanell, Joan; Macias, M. T.; Castro, Javier de; Perona, Rosario

doi:10.4161/15592294.2014.971626

Cited by 15 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DNA from H23S/R, H460S/R, A2780S/R, and OVCAR3S/R was isolated as described [ 48 ] and sent to the National Centre for Genome Analysis [ Centro Nacional de Análisis Genómico (CNAG)] for WGBS (GSE109317). Briefly, 2 µg of genomic DNA was mixed with unmethylated DNA from lambda phage in a proportion of 5 ng for each µg of genomic DNA.…”

Section: Methodsmentioning

confidence: 99%

An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells

et al. 2018

Self Cite

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are critical regulators of cell biology whose alteration can lead to the development of diseases such as cancer. The potential role of lncRNAs and their epigenetic regulation in response to platinum treatment are largely unknown. We analyzed four paired cisplatin-sensitive/resistant non-small cell lung cancer and ovarian cancer cell lines. The epigenetic landscape of overlapping and cis-acting lncRNAs was determined by combining human microarray data on 30,586 lncRNAs and 20,109 protein coding mRNAs with whole-genome bisulfite sequencing. Selected candidate lncRNAs were further characterized by PCR, gene-ontology analysis, and targeted bisulfite sequencing. Differential expression in response to therapy was observed more frequently in cis-acting than in overlapping lncRNAs (78% vs. 22%, fold change ≥1.5), while significantly altered methylation profiles were more commonly associated with overlapping lncRNAs (29% vs. 8%; P value <0.001). Moreover, overlapping lncRNAs contain more CpG islands (CGIs) (25% vs. 17%) and the majority of CGI-containing overlapping lncRNAs share these CGIs with their associated coding genes (84%). The differences in expression between sensitive and resistant cell lines were replicated in 87% of the selected candidates (P<0.05), while our bioinformatics approach identifying differential methylation was confirmed in all of the selected lncRNAs (100%). Five lncRNAs under epigenetic regulation appear to be involved in cisplatin resistance (AC091814.2, AC141928.1, RP11-65J3.1-002, BX641110, and AF198444). These novel findings provide new insights into epigenetic mechanisms and acquired resistance to cisplatin that highlight specific lncRNAs, some with unknown function, that may signal strategies in epigenetic therapies.

show abstract

Section: Methodsmentioning

confidence: 99%

An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The commercial kit for detecting methylation at IGFBP-3 gene is under development, and its use is directed toward the identification of NSCLC patients who could benefit more from concomitant chemotherapy-radiotherapy. 27,50,51 Lung cancer. Lung cancer is the worldwide leader in tumor-related deaths.…”

Section: Translational Applications Of Methylome Studies In Cancermentioning

confidence: 99%

The impact of next-generation sequencing on the DNA methylation–based translational cancer research

Soto

Rodriguez-Antolín

Vallespín

et al. 2016

Translational Research

Self Cite

View full text Add to dashboard Cite

Epigenetics is currently in an exponential phase of growth, constituting one of the most promising fields in science, particularly in cancer research. Impaired epigenetic processes can lead to abnormal gene activity or inactivity, causing cellular disorders that are closely associated with tumor initiation and progression. Thus, there is a pivotal role of massive sequencing techniques for epigenetics, which aim to find novel biomarkers, factors of prognosis and prediction, and targets for achieving personalized treatments. We present a brief description of the evolution of next-generation sequencing technologies and its coupling with DNA methylation analysis techniques, highlighting its future in translational medicine and presenting significant findings in several malignancies. We also expose critical topics related to the implementation of these approaches, which is expected to be affordable for most research centers in the near future.

show abstract

“…These data suggested that more advanced disease was associated with increased incidence of IGFBP-3 promoter methylation (Chang et al 2004). (Pernia et al 2014) using 40 NSCLC patients who were treated with chemotherapy with or without radiotherapy determined that patients with an unmethylated IGFBP-3 promoter would do better with chemotherapy alone as opposed to the combination therapy (Pernia et al 2014). …”

Section: Evidence For Epigenetic Alteration Of Igfbp-3 In Cancermentioning

confidence: 99%

Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer

Perks

Holly

2015

J. Cell Commun. Signal.

View full text Add to dashboard Cite

Epigenetics refers to heritable changes in gene expression that are independent of alterations in DNA sequence. It is now accepted that disruption of epigenetic mechanisms plays a key role in the pathogenesis of cancer: culminating in altered gene function and malignant cellular transformation. DNA methylation and histone modifications are the most widely studied changes but non-coding RNAs such as miRNAs are also considered part of the epigenetic machinery. The insulin-like growth factor (IGF) axis is composed of two ligands, IGF-I and -II, their receptors and six high affinity IGF binding proteins (IGFBPs). The IGF axis plays a key role in cancer development and progression. As IGFBP genes have consistently been identified among the most common to be aberrantly altered in tumours, this review will focus on epigenetic regulation of IGFBP-3 in cancer for which the majority of evidence has been obtained.

show abstract

Methylation status ofIGFBP-3as a useful clinical tool for deciding on a concomitant radiotherapy

Cited by 15 publications

References 34 publications

An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells

An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells

The impact of next-generation sequencing on the DNA methylation–based translational cancer research

Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer

Contact Info

Product

Resources

About